Labcorp Outlines Growth Strategy Focused on AI and Specialty Testing Through 2029
During its 2026 Investor Day, LabCorp reaffirmed its financial guidance for the year and outlined a long-term growth strategy through 2029. The company expects adjusted earnings per share between $18.10 and $18.55 in 2026, exceeding Wall Street estimates. It also projected sales of $14.71 billion to $14.83 billion for the year. Looking ahead, LabCorp aims for a compound annual revenue growth rate between 5% and 8%, with adjusted EPS growing at an 8.5%-11.5% CAGR through 2029. The company plans to expand its operating margin by up to 150 basis points over the same period, supported by free cash flow growth aligned with earnings. The strategic focus includes expanding specialty testing in oncology and neurology, strengthening partnerships for health systems and pharmaceutical companies, advancing personalized healthcare solutions, and integrating AI and robotics into operations. These initiatives are intended to drive innovation and maintain LabCorp’s leadership position.
Tickers: $LH
Topics: AI integration biopharma diagnostics earnings guidance healthcare